Elevation of angiogenic factor cysteine-rich 61 levels in vitreous of patients with proliferative diabetic retinopathy

Retina

Volumn 32, Issue 1, 2012, Pages 103-111

  You, Jian Jang ^a,b   Yang, Chung May ^c   Chen, Muh Shy ^c   Yang, Chang Hao ^c  

^a KEELUNG HOSPITAL   (Taiwan)

^b CHING KUO INSTITUTE OF MANAGEMENT AND HEALTH   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

angiogenesis; bevacizumab; cysteine rich 61; fibrosis; proliferative diabetic retinopathy; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CYSTEINE RICH PROTEIN 61; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; PREMEDICATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SEX DIFFERENCE; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CYSTEINE-RICH PROTEIN 61; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84855206903     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318219e4ad     Document Type: Article

References (32)

1. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care 2003;261:S99-S102. (Pubitemid 36934460)
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998;21:143-156. (Pubitemid 28030402)
3. Frank RN. Vascular endothelial growth factor-its role in retinal vascular proliferation. N Engl J Med 1994;331: 1519-1520. (Pubitemid 24356315)
4. Katsura Y, Okano T, Noritake M, et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care 1998;21: 1759-1763. (Pubitemid 28449821)
5. Hinton DR, Spee C, He S, et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 2004;27:758-764. (Pubitemid 38280546)
6. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1691-e1615.
7. Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008;146:211-217.
8. Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009;29:768-774.
9. Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216. (Pubitemid 351224097)
10. Schutze N, Kunzi-Rapp K, Wagemanns R, et al. Expression, purification, and functional testing of recombinant CYR61/CCN1. Protein Expr Purif 2005;42:219-225. (Pubitemid 40793414)
11. Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002;5:153-165. (Pubitemid 36687518)
12. You JJ, Yang CH, Chen MS, et al. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:3447-3455.
13. Brunner A, Chinn J, Neubauer M, et al. Identification of a gene family regulated by transforming growth factor-beta. DNA Cell Biol 1991;10:293-300.
14. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106: 254-260. (Pubitemid 34761308)
15. Wu KJ, Yee A, Zhu NL, Gordon EM, et al. Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury. Int J Mol Med 2000;6: 433-440.
16. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005;243:3-8.
17. Yang CM. Surgical treatment for severe diabetic macular edema with massive hard exudates. Retina 2000;20:121-125. (Pubitemid 30395705)
18. Kumagai K, Furukawa M, Ogino N, et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009;29:464-472.
19. Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 2006;124: 1457-1462. (Pubitemid 44537147)
20. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997;151:13-23. (Pubitemid 27283952)
21. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792. (Pubitemid 41215487)
22. Babic AM, Kireeva ML, Kolesnikova TV, et al. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355-6360. (Pubitemid 28249016)
23. Chen CC, Mo FE, Lau LF. The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J Biol Chem 2001;276:47329-47337.
24. Abe M, Sato Y. cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001;4:289-298. (Pubitemid 34832374)
25. Zhou D, Herrick DJ, Rosenbloom J, et al. Cyr61 mediates the expression of VEGF, alphav-integrin, and alpha-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cells. J Appl Physiol 2005;98: 2344-2354. (Pubitemid 40726936)
26. Kolesnikova TV, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998;16:747-754. (Pubitemid 28076085)
27. Jousssen AN, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452. (Pubitemid 39561611)
28. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84.
29. Lu M, Perez VL, Na N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 1999; 40:1808-1812. (Pubitemid 29297158)
30. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetics. Invest Ophthalmol Vis Sci 2001;42:2408-2413. (Pubitemid 32848873)
31. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 2008;3:e2675.
32. Jonas JB, Schmidbauer M, Rensch F. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol 2009;87:571-572.